Sue Yom | UCSF Health

Dr. Sue S. Yom

Claim this profile

University of California, San Francisco

Studies Squamous Cell Carcinoma
Studies Nasopharyngeal Cancer
10 reported clinical trials
20 drugs studied

Area of expertise

1

Squamous Cell Carcinoma

Sue S. Yom has run 4 trials for Squamous Cell Carcinoma. Some of their research focus areas include:

p16 negative
Stage III
Stage I
2

Nasopharyngeal Cancer

Sue S. Yom has run 3 trials for Nasopharyngeal Cancer. Some of their research focus areas include:

Stage III
Stage IV
Stage II

Affiliated Hospitals

Image of trial facility.

University Of California, San Francisco

Image of trial facility.

UCSF Medical Center-Mission Bay

Clinical Trials Sue S. Yom is currently running

Image of trial facility.

SBRT

for Adenoid Cystic Carcinoma

The aim of this study is to learn whether the early initiation of a specialized and focused type of radiation called stereotactic body radiation therapy (SBRT) will impact the progression of advanced adenoid cystic carcinoma, quality of life, and overall survival. The name(s) of the study intervention involved in this study is: * Stereotactic Body Radiation Therapy (SBRT)

Recruiting

1 award

N/A

13 criteria

Image of trial facility.

Radiation Therapy

for Nasopharyngeal Cancer

This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy \[IMRT\]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiation therapy (IMRT) is an advanced form of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Radiation therapy sometimes causes unwanted symptoms or side effects, including late effects such as hearing loss and dental problems. The severity of the side effects is related to the radiation dose received and the amount of tissue that received radiation. De-escalation IMRT uses lower doses of radiation based on a good response to induction chemotherapy. Giving de-escalated IMRT may be as effective as standard doses of IMRT in treating patients with EBV-associated nasopharyngeal cancer.

Recruiting

1 award

N/A

8 criteria

More about Sue S. Yom

Clinical Trial Related

4 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Sue S. Yom has experience with

  • Cisplatin
  • Nivolumab
  • Intensity-Modulated Radiation Therapy
  • Cetuximab
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Miracle Fruit Placebo Cube

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Sue S. Yom specialize in?

Is Sue S. Yom currently recruiting for clinical trials?

Are there any treatments that Sue S. Yom has studied deeply?

What is the best way to schedule an appointment with Sue S. Yom?

What is the office address of Sue S. Yom?

Is there any support for travel costs?